PT  - JOURNAL ARTICLE
AU  - Bayli DiVita Dean
AU  - Tyler Wildes
AU  - Joseph Dean
AU  - Oleg Yegorov
AU  - Changlin Yang
AU  - David Shin
AU  - Connor Francis
AU  - John W Figg
AU  - Mathew Sebastian
AU  - Laura Falceto Font
AU  - Dan Jin
AU  - Alexandra Reid
AU  - Ginger Moore
AU  - Brandon Fernandez
AU  - Brandon Wummer
AU  - Carmelle Kuizon
AU  - Duane Mitchell
AU  - Catherine T Flores
TI  - Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis
AID  - 10.1136/jitc-2022-004805
DP  - 2023 Feb 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e004805
VI  - 11
IP  - 2
4099  - http://jitc.bmj.com/content/11/2/e004805.short
4100  - http://jitc.bmj.com/content/11/2/e004805.full
SO  - J Immunother Cancer2023 Feb 01; 11
AB  - Background Glioma-induced immune dysregulation of the hematopoietic system has been described in a limited number of studies. In this study, our group further demonstrates that gliomas interrupt the cellular differentiation programming and outcomes of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow. HSPCs from glioma-bearing mice are reprogrammed and driven towards expansion of myeloid lineage precursors and myeloid-derived suppressor cells (MDSCs) in secondary lymphoid organs. However, we found this expansion is reversed by immunotherapy. Adoptive cellular therapy (ACT) has been demonstrably efficacious in multiple preclinical models of central nervous system (CNS) malignancies, and here we describe how glioma-induced dysfunction is reversed by this immunotherapeutic platform.Methods The impact of orthotopic KR158B-luc glioma on HSPCs was evaluated in an unbiased fashion using single cell RNAseq (scRNAseq) of lineage− cells and phenotypically using flow cytometry. Mature myeloid cell frequencies and function were also evaluated using flow cytometry. Finally, ACT containing total body irradiation, tumor RNA-pulsed dendritic cells, tumor-reactive T cells and HSPCs isolated from glioma-bearing or non-tumor-bearing mice were used to evaluate cell fate differentiation and survival.Results Using scRNAseq, we observed an altered HSPC landscape in glioma-bearing versus non-tumor-bearing mice . In addition, an expansion of myeloid lineage subsets, including granulocyte macrophage precursors (GMPs) and MDSCs, were observed in glioma-bearing mice relative to non-tumor-bearing controls. Furthermore, MDSCs from glioma-bearing mice demonstrated increased suppressive capacity toward tumor-specific T cells as compared with MDSCs from non-tumor-bearing hosts. Interestingly, treatment with ACT overcame these suppressive properties. When HSPCs from glioma-bearing mice were transferred in the context of ACT, we observed significant survival benefit and long-term cures in orthotopic glioma models compared with mice treated with ACT using non-glioma-bearing HSPCs.Data are available on reasonable request.